The present invention relates to
phosphodiesterase 4D7 (PDE4D7) for use as a marker for
prostate cancer, and the use of PDE4D7 as a marker for diagnosing, detecting, monitoring or prognosticating
prostate cancer or the progression of
prostate cancer. The present invention also relates to a composition for diagnosing, detecting, monitoring or prognosticating
prostate cancer or the progression of
prostate cancer, a corresponding method and
immunoassay, a method for diagnosing, monitoring or prognosticating
hormone-resistant
prostate cancer vs.
hormone-sensitive prostate cancer, a corresponding
immunoassay, a method of
data acquisition, an
immunoassay for diagnosing, detecting, monitoring or prognosticating prostate cancer or the progression of prostate cancer, a method of identifying an individual for eligibility for prostate
cancer therapy, an immunoassay for stratifying an individual or cohort of individuals with a prostate cancer
disease, an immunoassay for stratifying an individual with prostate cancer, as well as a pharmaceutical composition comprising a compound directly stimulating or modulating the activity of PDE4D7, a compound indirectly stimulating or modulating the activity of PDE4D7, the PDE4D7
protein or a biologically active equivalent thereof, a
nucleic acid encoding and expressing PDE4D7, a miRNA inhibitor specific for PDE4D7 miRNAs, a
demethylation agent and / or a
phosphodiesterase displacement factor.